表紙:血友病治療市場 - 世界の業界分析(2019年~2021年):成長動向と市場予測(2022年~2027年)
市場調査レポート
商品コード
1088279

血友病治療市場 - 世界の業界分析(2019年~2021年):成長動向と市場予測(2022年~2027年)

Hemophilia Treatment Market - Global Industry Analysis (2019 - 2021) - Growth Trends and Market Forecast (2022 - 2027)

出版日: | 発行: Fairfield Market Research | ページ情報: 英文 196 Pages | 納期: 2~5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
血友病治療市場 - 世界の業界分析(2019年~2021年):成長動向と市場予測(2022年~2027年)
出版日: 2022年05月05日
発行: Fairfield Market Research
ページ情報: 英文 196 Pages
納期: 2~5営業日
  • 全表示
  • 概要
  • 目次
概要

世界の血友病治療の市場規模は、2022年~2027年にかけて5.2%のCAGRで拡大し、2027年までに213億4,900万米ドルに達すると予測されています。

当レポートでは、世界の血友病治療市場について調査し、市場の概要とともに、治療タイプ別、適応症別、用途別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • 規制の枠組み
  • 臨床シナリオの価値フレームワーク
  • 血友病治療センター:包括的ケアモデル
  • 償還シナリオ
  • COVID-19の影響分析
  • 血友病市場情勢

第3章 世界の血友病治療市場の見通し、2019年~2027年

  • 世界の血友病治療市場の見通し、治療タイプ別、2019年~2027年
  • 世界の血友病治療市場の見通し、適応症別、2019年~2027年
  • 世界の血友病治療市場の見通し、用途別、2019年~2027年
  • 世界の血友病治療市場の見通し、地域別、2019~2027年

第4章 北米の血友病治療市場の見通し、2019年~2027年

第5章 欧州の血友病治療市場の見通し、2019年~2027年

第6章 アジア太平洋の血友病治療市場の見通し、2019年~2027年

第7章 その他の地域の血友病治療市場の見通し、2019年~2027年

第8章 競合情勢

  • 市場シェア分析、2021年
  • 企業プロファイル
    • Bayer AG
    • BioMarin Pharmaceuticals, Inc.
    • F. Hoffman La Roche Ltd.
    • Grifols S.A.
    • Sanofi
    • Takeda Pharmaceuticals Company Ltd.
    • CSL Behring
    • Medexus Pharmaceuticals Inc.
    • Novo Nordisk
    • Octapharma AG
    • Pfizer Inc.

第9章 付録

目次

Globally, the incidence of hemophilia has witnessed an uptick over the past few years. Classified as a rare disease, hemophilia occurs due to the absence/lack of a protein known as a clotting factor. It is divided into three main types namely, Hemophilia A, Hemophilia B, and Acquired Hemophilia. Owing to the increase in the incidence of hemophilia and the growing prevalence of blood clotting diseases in the adult population, healthcare professionals (HCPs) are highly driven to develop novel therapeutics to treat hemophilia. This trend is extremely viable for the global hemophilia treatment market as it has opened sound business opportunities for manufacturers across international markets. In the near future, innovation in hemophilia treatments, development of new procedures, and sound hemophilia awareness programs are poised to strengthen the global hemophilia treatment market, enabling it to reach a total market value of US$ 21, 349 million by 2027.

Key Insights and Trends Across Global Hemophilia Treatment Market

Between 2022 to 2027, the global hemophilia treatment market will grow at a promising CAGR of 5.2% owing to healthy market competition, aggressive pursuit of novel therapeutics, strategic partnerships by market players, and sound government rebates.

On the basis of application, the prophylaxis segment is poised to register the highest growth, reaching a total market valuation of US$ 8 billion by 2027.

Whereas, on the basis of treatment type, the recombinant factor concentrates segment is projected to contribute nearly 40% in terms of value.

Over the forecast period, in terms of treatment indication type, Hemophilia B is predicted to register a robust CAGR of ~6%, while Hemophilia A is expected to lead in terms of the total value generated which is expected to be approximately US$ 15 billion.

Favorable Outlook Towards Novel Therapeutics Set to Open Fresh Revenue Streams

Several advanced hemophilia treatment options have surfaced over the recent past, and various others are towards the last stage of clinical trials. Novel therapeutics viz., extended half-life factor concentrates (FVIII/FIX), hemophilia gene therapy, targeting of natural anticoagulant pathways, and biphasic antibodies, coupled with new clotting factor concentrates (CFCs), have significantly decreased the burden of patient care. Consequently, the demand for new hemophilia treatments has dramatically increased. However, concerns around treatment efficacy and overall cost are projected to restrict the rapid market growth in the coming years - a challenge that is being overcome through government rebates and rigorous R&D initiatives by public and private entities.

North America Sustains Position as Market Leader

North America continues to command the highest market share in the global hemophilia treatment market. It recorded a total market value of US$ 6,481 million in 2022, and by 2027, this market value is poised to reach US$ 7,899 million, growing at a CAGR of 4.0%. In North America, major factors harnessing growth in the global hemophilia treatment market include the presence of key industry players, government rebates, and higher national income. Moreover, the availability of modern treatments at relatively lower prices is expected to enable the Asia Pacific to register a robust CAGR of 7.2% over the assessment period.

Major Market Players

Some of the prominent market player in the global hemophilia treatment market include: Pfizer Inc, Medexus Pharmaceuticals Inc., Novo Nordisk, Octapharma AG, Takeda Pharmaceuticals Company Ltd., BioMarin Pharmaceuticals, Inc., CSL Behring, Bayer AG, F. Hoffman La Roche Ltd., Grifols S.A., and Sanofi among others.

Post Sale Support, Research Updates & Offerings

  • The report will be prepared in a PPT format and will be delivered in a PDF format.
  • Additionally, Market Estimation and Forecast numbers will be shared in Excel Workbook.
  • If a report being sold was published over a year ago, we will offer a complimentary copy of the updated research report along with Market Estimation and Forecast numbers within 2-3 weeks' time of the sale.
  • If we update this research study within the next 2 quarters, post purchase of the report, we will offer a Complimentary copy of the updated Market Estimation and Forecast numbers in Excel Workbook.
  • If there is a geopolitical conflict, pandemic, recession, and the like which can impact global economic scenario and business activity, which might entirely alter the market dynamics or future projections in the industry, we will create a Research Update upon your request at a nominal charge.

Table of Contents

1. Executive Summary

  • 1.1. Global Hemophilia Treatment Market Outlook, 2019 - 2027 (US$ Million)
  • 1.2. Global Hemophilia Treatment Market Incremental Opportunity, 2022- 2027 (US$ Million)
  • 1.3. Key Industry Trends

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Market Drivers
    • 2.2.2. Market Threats
    • 2.2.3. Market Opportunities
  • 2.3. Regulatory Framework
  • 2.4. Value Framework of Clinical Scenarios
  • 2.5. Hemophilia Treatment Centres: Comprehensive Care Model
  • 2.6. Reimbursement Scenario
  • 2.7. COVID 19 Impact Analysis
  • 2.8. Hemophilia Market Landscape

3. Global Hemophilia Treatment Market Outlook, 2019 - 2027

  • 3.1. Global Hemophilia Treatment Market Outlook, By Treatment Type, 2019 - 2027
    • 3.1.1. Key Highlights
    • 3.1.2. Global Hemophilia Treatment Market Outlook, by Treatment Type, Value (US$ Million), 2019 - 2027
      • 3.1.2.1. Plasma Derived Factor Concentrates
      • 3.1.2.2. Recombinant Factor Concentrates
      • 3.1.2.3. Alternative Coagulation Promoters
      • 3.1.2.4. Others
    • 3.1.3. Global Hemophilia Treatment Market Share and BPS Analysis, by Treatment Type, Value, 2022 and 2027
    • 3.1.4. Global Hemophilia Treatment Market Attractiveness Analysis, by Treatment Type, Value, 2022 - 2027
  • 3.2. Global Hemophilia Treatment Market Outlook, By Indication Type, 2019 - 2027
    • 3.2.1. Key Highlights
    • 3.2.2. Global Hemophilia Treatment Market Outlook, by Indication Type, Value (US$ Million), 2019 - 2027
      • 3.2.2.1. Hemophilia A
      • 3.2.2.2. Hemophilia B
      • 3.2.2.3. Acquired Hemophilia
    • 3.2.3. Global Hemophilia Treatment Market Share and BPS Analysis, by Indication Type, Value, 2022 and 2027
    • 3.2.4. Global Hemophilia Treatment Market Attractiveness Analysis, by Indication Type, Value, 2022 - 2027
  • 3.3. Global Hemophilia Treatment Market Outlook, By Application, 2019 - 2027
    • 3.3.1. Key Highlights
    • 3.3.2. Global Hemophilia Treatment Market Outlook, by Application, Value (US$ Million), 2019 - 2027
      • 3.3.2.1. Prophylaxis
      • 3.3.2.2. On Demand
      • 3.3.2.3. Surgery
      • 3.3.2.4. Immune Tolerance Induction (ITI)
      • 3.3.2.5. Others
    • 3.3.3. Global Hemophilia Treatment Market Share and BPS Analysis, by Application Value, 2022 and 2027
    • 3.3.4. Global Hemophilia Treatment Market Attractiveness Analysis, by Application, Value 2022 - 2027
  • 3.4. Global Hemophilia Treatment Market Outlook, By Region, 2019 - 2027
    • 3.4.1. Key Highlights
    • 3.4.2. Global Hemophilia Treatment Market Outlook, by Region, Value (US$ Million), 2019 - 2027
      • 3.4.2.1. North America
      • 3.4.2.2. Europe
      • 3.4.2.3. Asia Pacific
      • 3.4.2.4. Rest of the World
    • 3.4.3. Global Hemophilia Treatment Market Share and BPS Analysis, by Region, Value, 2022 and 2027
    • 3.4.4. Global Hemophilia Treatment Market Attractiveness Analysis, by Region, Value, 2022 - 2027

4. North America Hemophilia Treatment Market Outlook, 2019 - 2027

  • 4.1. North America Hemophilia Treatment Market Outlook, By Treatment Type, 2019 - 2027
    • 4.1.1. Key Highlights
    • 4.1.2. North America Hemophilia Treatment Market Outlook, by Country, Value (US$ Million), 2019 - 2027
      • 4.1.2.1. U.S.
      • 4.1.2.2. Canada
    • 4.1.3. North America Hemophilia Treatment Market Outlook, by Treatment Type, Value (US$ Million), 2019 - 2027
      • 4.1.3.1. Plasma Derived Factor Concentrates
      • 4.1.3.2. Recombinant Factor Concentrates
      • 4.1.3.3. Alternative Coagulation Promotors
      • 4.1.3.4. Others
    • 4.1.4. North America Hemophilia Treatment Market Share and BPS Analysis, by Treatment Type, Value, 2022 and 2027
    • 4.1.5. North America Hemophilia Treatment Market Attractiveness Analysis, by Treatment Type, Value, 2022 - 2027
  • 4.2. North America Hemophilia Treatment Market Outlook, By Indication Type, 2019 - 2027
    • 4.2.1. Key Highlights
    • 4.2.2. North America Hemophilia Treatment Market Outlook, by Indication Type, Value (US$ Million), 2019 - 2027
      • 4.2.2.1. Hemophilia A
      • 4.2.2.2. Hemophilia B
      • 4.2.2.3. Acquired Hemophilia
    • 4.2.3. North America Hemophilia Treatment Market Share and BPS Analysis, by Indication Value, 2022 and 2027
    • 4.2.4. North America Hemophilia Treatment Market Attractiveness Analysis, by Indication Type Value, 2022 - 2027
  • 4.3. North America Hemophilia Treatment Market Outlook, By Application, 2019 - 2027
    • 4.3.1. Key Highlights
    • 4.3.2. North America Hemophilia Treatment Market Outlook, by Application, Value (US$ Million) 2019 - 2027
      • 4.3.2.1. Prophylaxis
      • 4.3.2.2. On Demand
      • 4.3.2.3. Surgery
      • 4.3.2.4. Immune Tolerance Induction (ITI)
      • 4.3.2.5. Others
    • 4.3.3. North America Hemophilia Treatment Market Share and BPS Analysis, by Application, Value, 2022 and 2027
    • 4.3.4. North America Hemophilia Treatment Market Attractiveness Analysis, by Application, Value, 2022 - 2027

5. Europe Hemophilia Treatment Market Outlook, 2019 - 2027

  • 5.1. Europe Hemophilia Treatment Market Outlook, By Treatment Type, 2019 - 2027
    • 5.1.1. Key Highlights
    • 5.1.2. Europe Hemophilia Treatment Market Outlook, by Country, Value (US$ Million), 2019 - 2027
      • 5.1.2.1. U.K.
      • 5.1.2.2. France
      • 5.1.2.3. Germany
      • 5.1.2.4. Italy
      • 5.1.2.5. Spain
      • 5.1.2.6. Rest of Europe
    • 5.1.3. Europe Hemophilia Treatment Market Outlook, by Treatment Type, Value (US$ Million), 2019 - 2027
      • 5.1.3.1. Plasma Derived Factor Concentrates
      • 5.1.3.2. Recombinant Factor Concentrates
      • 5.1.3.3. Alternative Coagulation Promotors
      • 5.1.3.4. Others
    • 5.1.4. Europe Hemophilia Treatment Market Share and BPS Analysis, by Treatment Type, Value, 2022 and 2027
    • 5.1.5. Europe Hemophilia Treatment Market Attractiveness Analysis, by Treatment Type, Value, 2022 - 2027
  • 5.2. Europe Hemophilia Treatment Market Outlook, By Indication Type, 2019 - 2027
    • 5.2.1. Key Highlights
    • 5.2.2. Europe Hemophilia Treatment Market Outlook, by Indication Type, Value (US$ Million), 2019 - 2027
      • 5.2.2.1. Hemophilia A
      • 5.2.2.2. Hemophilia B
      • 5.2.2.3. Acquired Hemophilia
    • 5.2.3. Europe Hemophilia Treatment Market Share and BPS Analysis, by Indication Value, 2022 and 2027
    • 5.2.4. Europe Hemophilia Treatment Market Attractiveness Analysis, by Indication Type Value, 2022 - 2027
  • 5.3. Europe Hemophilia Treatment Market Outlook, By Application, 2019 - 2027
    • 5.3.1. Key Highlights
    • 5.3.2. Europe Hemophilia Treatment Market Outlook, by Application, Value (US$ Million) 2019 - 2027
      • 5.3.2.1. Prophylaxis
      • 5.3.2.2. On Demand
      • 5.3.2.3. Surgery
      • 5.3.2.4. Immune Tolerance Induction (ITI)
      • 5.3.2.5. Others
    • 5.3.3. Europe Hemophilia Treatment Market Share and BPS Analysis, by Application, Value, 2022 and 2027
    • 5.3.4. Europe Hemophilia Treatment Market Attractiveness Analysis, by Application, Value, 2022 - 2027

6. Asia Pacific Hemophilia Treatment Market Outlook, 2019 - 2027

  • 6.1. Asia Pacific Hemophilia Treatment Market Outlook, By Treatment Type, 2019 - 2027
    • 6.1.1. Key Highlights
    • 6.1.2. Asia Pacific Hemophilia Treatment Market Outlook, by Country, Value (US$ Million), 2019 - 2027
      • 6.1.2.1. India
      • 6.1.2.2. Japan
      • 6.1.2.3. China
      • 6.1.2.4. Australia
      • 6.1.2.5. Rest of Asia Pacific
    • 6.1.3. Asia Pacific Hemophilia Treatment Market Outlook, by Treatment Type, Value (US$ Million), 2019 - 2027
      • 6.1.3.1. Plasma Derived Factor Concentrates
      • 6.1.3.2. Recombinant Factor Concentrates
      • 6.1.3.3. Alternative Coagulation Promotors
      • 6.1.3.4. Others
    • 6.1.4. Asia Pacific Hemophilia Treatment Market Share and BPS Analysis, by Treatment Type, Value, 2022 and 2027
    • 6.1.5. Asia Pacific Hemophilia Treatment Market Attractiveness Analysis, by Treatment Type, Value, 2022 - 2027
  • 6.2. Asia Pacific Hemophilia Treatment Market Outlook, By Indication Type, 2019 - 2027
    • 6.2.1. Key Highlights
    • 6.2.2. Asia Pacific Hemophilia Treatment Market Outlook, by Indication Type, Value (US$ Million), 2019 - 2027
      • 6.2.2.1. Hemophilia A
      • 6.2.2.2. Hemophilia B
      • 6.2.2.3. Acquired Hemophilia
    • 6.2.3. Asia Pacific Hemophilia Treatment Market Share and BPS Analysis, by Indication Value, 2022 and 2027
    • 6.2.4. Asia Pacific Hemophilia Treatment Market Attractiveness Analysis, by Indication Type Value, 2022 - 2027
  • 6.3. Asia Pacific Hemophilia Treatment Market Outlook, By Application, 2019 - 2027
    • 6.3.1. Key Highlights
    • 6.3.2. Asia Pacific Hemophilia Treatment Market Outlook, by Application, Value (US$ Million) 2019 - 2027
      • 6.3.2.1. Prophylaxis
      • 6.3.2.2. On Demand
      • 6.3.2.3. Surgery
      • 6.3.2.4. Immune Tolerance Induction (ITI)
      • 6.3.2.5. Others
    • 6.3.3. Asia Pacific Hemophilia Treatment Market Share and BPS Analysis, by Application, Value, 2022 and 2027
    • 6.3.4. Asia Pacific Hemophilia Treatment Market Attractiveness Analysis, by Application, Value, 2022 - 2027

7. Rest of the World Hemophilia Treatment Market Outlook, 2019 - 2027

  • 7.1. Rest of the World Hemophilia Treatment Market Outlook, By Treatment Type, 2019 - 2027
    • 7.1.1. Key Highlights
    • 7.1.2. Rest of the World Hemophilia Treatment Market Outlook, by Country, Value (US$ Million), 2019 - 2027
      • 7.1.2.1. Latin America
      • 7.1.2.2. Middle East & Africa
    • 7.1.3. Rest of the World Hemophilia Treatment Market Outlook, by Treatment Type, Value (US$ Million), 2019 - 2027
      • 7.1.3.1. Plasma Derived Factor Concentrates
      • 7.1.3.2. Recombinant Factor Concentrates
      • 7.1.3.3. Alternative Coagulation Promotors
      • 7.1.3.4. Others
    • 7.1.4. Rest of the World Hemophilia Treatment Market Share and BPS Analysis, by Treatment Type, Value, 2022 and 2027
    • 7.1.5. Rest of the World Hemophilia Treatment Market Attractiveness Analysis, by Treatment Type, Value, 2022 - 2027
  • 7.2. Rest of the World Hemophilia Treatment Market Outlook, By Indication Type, 2019 - 2027
    • 7.2.1. Key Highlights
    • 7.2.2. Rest of the World Hemophilia Treatment Market Outlook, by Indication Type, Value (US$ Million), 2019 - 2027
      • 7.2.2.1. Hemophilia A
      • 7.2.2.2. Hemophilia B
      • 7.2.2.3. Acquired Hemophilia
    • 7.2.3. Rest of the World Hemophilia Treatment Market Share and BPS Analysis, by Indication Value, 2022 and 2027
    • 7.2.4. Rest of the World Hemophilia Treatment Market Attractiveness Analysis, by Indication Type Value, 2022 - 2027
  • 7.3. Rest of the World Hemophilia Treatment Market Outlook, By Application, 2019 - 2027
    • 7.3.1. Key Highlights
    • 7.3.2. Rest of the World Hemophilia Treatment Market Outlook, by Application, Value (US$ Million) 2019 - 2027
      • 7.3.2.1. Prophylaxis
      • 7.3.2.2. On Demand
      • 7.3.2.3. Surgery
      • 7.3.2.4. Immune Tolerance Induction (ITI)
      • 7.3.2.5. Others
    • 7.3.3. Rest of the World Hemophilia Treatment Market Share and BPS Analysis, by Application, Value, 2022 and 2027
    • 7.3.4. Rest of the World Hemophilia Treatment Market Attractiveness Analysis, by Application, Value, 2022 - 2027

8. Competitive Landscape

  • 8.1. Market Share Analysis, 2021
  • 8.2. Company Profiles
    • 8.2.1. Bayer AG
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product Portfolio
      • 8.2.1.4. Pipeline Analysis

Above details will include, but not be limited to below list of companies based on availability

    • 8.2.2. BioMarin Pharmaceuticals, Inc.
    • 8.2.3. F. Hoffman La Roche Ltd.
    • 8.2.4. Grifols S.A.
    • 8.2.5. Sanofi
    • 8.2.6. Takeda Pharmaceuticals Company Ltd.
    • 8.2.7. CSL Behring
    • 8.2.8. Medexus Pharmaceuticals Inc.
    • 8.2.9. Novo Nordisk
    • 8.2.10. Octapharma AG
    • 8.2.11. Pfizer Inc.

9. Appendix

  • 9.1. Research Methodology
  • 9.2. Report Specific Research Approach